Insider Trading activities at Ani Pharmaceuticals Inc (ANIP) , Part 2

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ani Pharmaceuticals Inc (ANIP) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ani Pharmaceuticals Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1023024.

Total stock buying since 2015: $2,334,855.
Total stock sales since 2015: $211,720,298.
Total stock option exercises since 2015: $9,126,408.


 1   2 
24 insiders reported insider trading activities at Ani Pharmaceuticals Inc (ANIP):
Insider trading activities of Pera Antonio R
Insider trading activities of Nash David
Insider trading activities of Lalwani Nikhil
Insider trading activities of Tannenbaum Renee P
Insider trading activities of Gassert Chad
Insider trading activities of Schrepfer Robert W
Insider trading activities of Davis Krista
Insider trading activities of Shanmugam Muthusamy
Insider trading activities of Thoma Jeanne
Insider trading activities of Przybyl Arthur
Insider trading activities of Marken James G.
Insider trading activities of Cook Meredith
Insider trading activities of Carey Stephen P.
Insider trading activities of Arnold Charlotte C.
Insider trading activities of Walsh Patrick D
Insider trading activities of Marshbanks Tracy
Insider trading activities of Gutwerg Ori
Insider trading activities of Rowland Thomas Andrew
Insider trading activities of Leonard Matthew J
Insider trading activities of Holubow Fred
Insider trading activities of Raynor Daniel
Insider trading activities of Brown Robert E. Jr
Insider trading activities of Mutz Christopher
Insider trading activities of Haughey Thomas

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Ani Pharmaceuticals Inc (ANIP).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2026 0 $0 126,891 $9,778,118 3,312 $163,977
2025 0 $0 459,462 $40,030,556 50,300 $2,333,947
2024 0 $0 569,517 $36,033,709 42,550 $1,538,726
2023 0 $0 803,476 $46,079,827 30,535 $961,359
2022 32,224 $890,381 218,066 $8,373,071 0 $0
2021 10,572 $406,621 0 $0 0 $0
2020 20,000 $662,880 0 $0 0 $0
2019 3,945 $272,598 186,954 $12,880,939 14,005 $417,593
2018 0 $0 331,994 $20,658,595 107,148 $1,822,073
2016 0 $0 49,955 $3,346,573 75,082 $1,022,441
2015 2,500 $102,375 548,500 $34,538,910 68,143 $866,292


Table 3. Detailed insider trading at Ani Pharmaceuticals Inc (ANIP) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2023-08-28 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 25,000 63.06 1,576,500
2023-08-23 Gutwerg Ori (SVP, GENERICS) Sale 15,561 62.39 970,850
2023-08-23 Gutwerg Ori (SVP, GENERICS) Option Ex 13,502 31.49 425,177
2023-08-23 Marken James G. (SVP OPS & PROD DEV) Sale 3,932 63.00 247,716
2023-08-23 Marken James G. (SVP OPS & PROD DEV) Option Ex 5,417 36.80 199,318
2023-08-16 Brown Robert E. Jr Sale 200,000 58.50 11,700,000
2023-08-15 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 22,110 61.60 1,361,976
2023-08-15 Lalwani Nikhil (PRESIDENT & CEO) Sale 11,616 61.13 710,086
2023-08-15 Lalwani Nikhil (PRESIDENT & CEO) Option Ex 11,616 29.00 336,864
2023-08-14 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 27,890 61.15 1,705,473
2023-08-14 Pera Antonio R Sale 3,000 60.37 181,110
2023-08-14 Carey Stephen P. (SVP & CFO) Sale 17,639 61.37 1,082,505
2023-08-11 Lalwani Nikhil (PRESIDENT & CEO) Sale 56,666 57.75 3,272,461
2023-08-01 Gassert Chad (SVP - CORP. DEV. & STRATEGY) Sale 20,000 51.06 1,021,200
2023-07-21 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 11,500 52.56 604,440
2023-07-20 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 6,000 51.52 309,120
2023-07-19 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 5,969 51.48 307,284
2023-07-18 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 6,700 51.84 347,328
2023-07-17 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 9,831 51.06 501,970
2023-07-14 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 10,000 50.43 504,300
2023-07-03 Gassert Chad (SVP - CORP. DEV. & STRATEGY) Sale 20,000 53.43 1,068,600
2023-06-22 Gassert Chad (SVP - CORP. DEV. & STRATEGY) Sale 20,000 51.32 1,026,400
2023-06-22 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 13,500 51.38 693,630
2023-06-21 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 11,843 51.95 615,243
2023-06-20 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Sale 14,657 51.93 761,138
2022-12-01 Brown Robert E. Jr Sale 200,000 38.50 7,700,000
2022-08-15 Marken James G. (SVP OPS & PROD DEV) Sale 5,172 37.79 195,465
2022-08-12 Marken James G. (SVP OPS & PROD DEV) Sale 12,894 37.04 477,606
2022-03-21 Gassert Chad (SVP - CORP. DEV. & STRATEGY) Buy 5,000 27.87 139,345
2022-03-21 Lalwani Nikhil (PRESIDENT & CEO) Buy 7,224 27.68 199,996
2022-03-21 Walsh Patrick D Buy 5,000 27.76 138,795
2022-03-18 Gassert Chad (SVP - CORP. DEV. & STRATEGY) Buy 5,000 27.15 135,745
2022-03-17 Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) Buy 10,000 27.65 276,500
2021-12-20 Thoma Jeanne Buy 1,072 46.47 49,820
2021-12-07 Pera Antonio R Buy 3,000 42.27 126,795
2021-12-06 Haughey Thomas Buy 2,500 39.38 98,450
2021-03-15 Walsh Patrick D Buy 4,000 32.89 131,556
2020-11-09 Walsh Patrick D Buy 5,000 25.96 129,800
2020-08-10 Walsh Patrick D (CHAIRMAN, INTERIM PRES. & CEO) Buy 10,000 30.76 307,570
2020-03-04 Haughey Thomas Buy 3,000 45.05 135,150
2020-03-03 Haughey Thomas Buy 2,000 45.18 90,360
2019-08-20 Brown Robert E. Jr Sale 5,512 68.18 375,808
2019-08-19 Brown Robert E. Jr Sale 2,067 68.30 141,176
2019-08-16 Brown Robert E. Jr Sale 26,349 68.09 1,794,103
2019-08-15 Brown Robert E. Jr Sale 9,315 69.34 645,902
2019-08-14 Brown Robert E. Jr Sale 26,360 69.89 1,842,300
2019-08-13 Brown Robert E. Jr Sale 20,821 71.77 1,494,323
2019-08-12 Brown Robert E. Jr Sale 21,016 71.45 1,501,593
2019-08-09 Brown Robert E. Jr Sale 19,860 71.70 1,423,962
2019-05-24 Nash David Buy 1,445 68.76 99,358
2019-05-17 Marken James G. (SVP Ops & Prod Dev) Sale 8,907 70.67 629,457
2019-05-16 Brown Robert E. Jr Option Ex 2,209 19.68 43,473
2019-05-15 Haughey Thomas Buy 2,500 69.30 173,240
2019-05-14 Marken James G. (SVP Ops & Prod Dev) Sale 4,917 70.31 345,714
2019-05-13 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Sale 2,409 71.13 171,352
2019-03-19 Przybyl Arthur (President and CEO) Sale 2,823 63.51 179,288
2019-03-18 Przybyl Arthur (President and CEO) Sale 24,802 63.53 1,575,671
2019-03-13 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Sale 4,651 64.43 299,645
2019-03-13 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Option Ex 4,651 33.00 153,483
2019-03-12 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Sale 7,145 64.47 460,645
2019-03-12 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Option Ex 7,145 30.88 220,637
2018-09-11 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Option Ex 28,688 6.60 189,340
2018-05-16 Marshbanks Tracy Sale 25,706 62.40 1,604,054
2018-05-15 Marshbanks Tracy Sale 7,024 62.05 435,839
2018-05-14 Marshbanks Tracy Sale 5,506 62.35 343,299
2018-05-10 Marshbanks Tracy Sale 41,914 62.09 2,602,230
2018-05-09 Marshbanks Tracy Sale 20,517 62.05 1,273,079
2018-04-18 Marshbanks Tracy Sale 33,200 62.09 2,061,388
2018-03-20 Holubow Fred Option Ex 2,000 .00 0
2018-03-19 Raynor Daniel Sale 5,313 60.62 322,074
2018-03-15 Raynor Daniel Sale 1,902 61.50 116,973
2018-03-14 Marshbanks Tracy Sale 1,912 63.10 120,647
2018-03-14 Przybyl Arthur (President and CEO) Sale 10,000 62.03 620,300
2018-03-14 Raynor Daniel Sale 1,919 62.02 119,016
2018-03-13 Przybyl Arthur (President and CEO) Sale 30,000 62.08 1,862,250
2018-03-13 Raynor Daniel Sale 18,117 62.20 1,126,877
2018-03-12 Marshbanks Tracy Sale 12,269 63.03 773,315
2018-03-12 Przybyl Arthur (President and CEO) Option Ex 15,723 6.36 99,998
2018-03-12 Raynor Daniel Sale 7,928 62.88 498,512
2018-03-09 Marshbanks Tracy Sale 36,561 63.01 2,303,708
2018-03-08 Marshbanks Tracy Sale 15,391 63.08 970,864
2018-03-05 Marken James G. (SVP Ops & Prod Dev) Sale 4,177 61.92 258,639
2018-03-05 Marken James G. (SVP Ops & Prod Dev) Option Ex 18,001 19.68 354,259
2018-03-01 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Sale 28,652 61.82 1,771,352
2018-03-01 Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) Option Ex 18,750 28.76 539,250
2018-03-01 Przybyl Arthur (President and CEO) Sale 23,986 61.46 1,474,179
2018-03-01 Przybyl Arthur (President and CEO) Option Ex 23,986 26.65 639,226
2016-11-15 Brown Robert E. Jr Option Ex 5,458 19.68 107,413
2016-08-22 Przybyl Arthur (President and CEO) Sale 37,455 66.97 2,508,361
2016-08-22 Przybyl Arthur (President and CEO) Option Ex 53,178 15.24 810,432
2016-08-08 Schrepfer Robert W (VP Bus Dev & Con Mfg) Sale 12,500 67.06 838,212
2016-01-08 Przybyl Arthur (President and CEO) Option Ex 16,446 6.36 104,596
2015-12-18 Marken James G. (Vice President, Operations) Sale 3,500 43.26 151,410
2015-11-12 Przybyl Arthur (President and CEO) Buy 2,500 40.95 102,375
2015-09-25 Arnold Charlotte C. (Vice President and CFO) Option Ex 19,060 19.68 375,100
2015-09-02 Arnold Charlotte C. (Vice President and CFO) Option Ex 2,106 33.00 69,498
2015-08-10 Przybyl Arthur (President and CEO) Option Ex 10,000 6.36 63,600
2015-07-17 Marken James G. (Vice President, Operations) Option Ex 7,395 6.36 47,032
2015-06-18 Schrepfer Robert W (VP Bus Dev & Con Mfg) Option Ex 9,062 6.60 59,809
2015-05-13 Marken James G. (Vice President, Operations) Option Ex 9,020 19.68 177,513
2015-05-07 Przybyl Arthur (President and CEO) Option Ex 5,000 6.36 31,800
2015-05-06 Arnold Charlotte C. (VP and CFO) Option Ex 4,000 6.36 25,440
2015-05-06 Schrepfer Robert W (VP Bus Dev & Con Mfg) Option Ex 2,500 6.60 16,500
2015-03-19 Marken James G. (Vice President, Operations) Sale 15,000 66.50 997,500
2015-03-12 Marshbanks Tracy (Director) Sale 210,000 63.00 13,230,000
2015-03-12 Arnold Charlotte C. (Vice President and CFO) Sale 45,000 63.00 2,835,000
2015-03-12 Przybyl Arthur (President and CEO) Sale 75,000 63.00 4,725,000
2015-03-12 Raynor Daniel Sale 200,000 63.00 12,600,000
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of ANIP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ani Pharmaceuticals Inc (symbol ANIP, CIK number 1023024) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.